Recombinant Mouse BTNL2/Butyrophilin-like Protein 2 Protein (His Tag) | PKSM041354

Recombinant Mouse BTNL2/Butyrophilin-like Protein 2 Protein (His Tag) | PKSM041354 | Gentaur US, UK & Europe Disrtribition

Synonyms: Butyrophilin-like protein 2; Btnl2; Gm315; Ng9

Active Protein: N/A

Activity: Recombinant Mouse Butyrophilin-like Protein 2 is produced by our Mammalian expression system and the target gene encoding Asp27-Ser452 is expressed with a 6His tag at the C-terminus.

Protein Construction: Recombinant Mouse Butyrophilin-like Protein 2 is produced by our Mammalian expression system and the target gene encoding Asp27-Ser452 is expressed with a 6His tag at the C-terminus.

Fusion Tag: C-His

Species: Mouse

Expressed Host: Human Cells

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Purity: > 95 % as determined by reducing SDS-PAGE.

Endotoxin: < 1.0 EU per μg as determined by the LAL method.

Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Molecular Mass: 48.6 kDa

Formulation: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4.

Reconstitution: Please refer to the printed manual for detailed information.

Background: Butyrophilin-like 2 (BTNL2) is a member of the BTN/MOG Ig-superfamily and functions as a negative regulator of immune cell activation. Mouse BTNL2 is type I transmembrane glycoprotein that contains an extracellular domain (ECD), a transmembrane region and a short cytoplasmic domain. The ECD features two V-type Ig-like domains, two C-type Ig-like domains, and four glycosylation sites. BTNL2 is expressed in epithelial cells of the small intestine, colonic dendritic cells, and in cells of the lymph node. BTNL2 expression is upregulated in T cells following activation, a characteristic BTNL2 shares with the homologous B7 family of costimulatory molecules. BTNL2 negatively regulates T cells by inhibiting proliferation and inflammatory cytokine secretion. It also increases the expression of FoxP3 in T cells to promote regulatory T cell development. Single nucleotide polymorphisms in BTNL2 are associated with a risk for sporadic prostate cancer, rheumatoid arthritis, sarcoidosis, ulcerative colitis, and other inflammatory diseases.

Research Area: N/A